ZT003 / Beijing QL Biopharma - LARVOL DELTA

A novel GLP-1/FGF21 dual agonist ZT003 has therapeutic potential for obesity, MASH and SHTG (EASD 2024) - "When tested in DIO obese mice and db/db diabetic obesity mice, ZT003 demonstrated synergistic, sustained, and superior body weight reduction and glucose-lowering effect versus semaglutide, tirzepatide and YH25724... In conclusion, this novel GLP-1/FGF21 fusion protein in animals reveals therapeutically efficacious to treat obesity, MASH and SHTG, thus demonstrating the promise of the poly-pharmaceutical approach in metabolic drug discovery and development."

Late-breaking abstract • Diabetes • Hypertriglyceridemia • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus • FGF21 • KLB